Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of filgotinib in adults with ulcerative colitis
2024-516199-14-00Phase 3Completed
- Sponsor
- Alfasigma
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of filgotinib in autoimmune colitis, sponsored by Alfasigma. Primary endpoint: Safety. Started Apr 2017; status: completed.
02
Drugs
filgotinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-516199-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516199-14-00.